Published on October 23, 2013 at 3:25 PM
The MEDICREA Group (FR0004178572-ALMED), which specializes in the development of innovative surgical technologies for the treatment of spinal pathologies, listed on Alternext by NYSE - Euronext Paris, announces its sales for the third quarter of 2013, ended September 30.
In the third quarter, the Group recorded over 60% of its sales on the U.S. market, with sales in US dollars increasing by 29% compared with the third quarter of 2012. In euros, the increase over the period was 23% because of a negative currency exchange impact.
"We are accelerating our development in the United States via our two distribution networks: direct and indirect. With the majority of our U.S. user surgeons attending the world's largest scientific congress (SRS) devoted to scoliosis for an entire week in September, a congress held in Lyon for the first time, our third quarter performance could have been even better. However, this event did provide the Group with a unique opportunity to highlight its expertise and ambitions amongst U.S. opinion leaders", says Denys SOURNAC, Chairman and CEO of MEDICREA.
At Group level, quarterly sales were up 4% over the same period of 2012 in a market that remains unsettled, essentially in Europe because of the pricing cuts imposed by national health system reforms. "Our growth was moderate last quarter but, with a center of gravity that is gradually shifting to the United States, our gross margin continues to improve. Indeed it rose above 80% in the third quarter", adds Denys SOURNAC.
The Group is reaffirming its objective of recording a significant operating profit and net profit over 2013, a sharp improvement compared with the previous year.
Next publication: 2013 annual sales: January 14, 2014, after market.